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ABO Blood Group Antigens as a 
Model of Studying Protein-Protein 
Interactions
Frida N. Gylmiyarova, Elena Ryskina, Nataliya Kolotyeva, 
Valeriia Kuzmicheva and Oksana Gusyakova
Abstract
This work presents a research of intermolecular interactions on the example of 
the antigen antibody interactions of the ABO system. This model could be suc-
cessfully used in the future due to the lack of knowledge in the area of the ABO 
antigen’s behavior as a biomolecule and the integration of these structures into 
chain of metabolic processes in a human being. Using computer PASS system (“in 
silico” research), we describe the possible biological effects of pyruvate, lactate, and 
antigen determinants A and B. Glycoproteins A and B are very perspective to study 
as biological active connectors due to the wide range of their biological effects. The 
obtained knowledge proves that ABO antigen, as well as other glycoprotein conju-
gates, could play an important role in intercellular adhesion and signal transmis-
sion, which could be used in perspective in personalized medicine, target therapy, 
and evaluation of lab results in clinical practice.
Keywords: ABO blood groups, protein-protein interaction, computer modeling, 
biological activity
1. Introduction
Erythrocytes are the most common blood cells in the human body. They present 
on their surface a huge number of different receptors and antigens, which explain 
their multiple biological functions. Since 1900, when Carl Landsteiner first found 
red blood cell antigens and named them ABO blood group system, a big step 
forward was made by scientists in this direction. Up to now, over 35 blood groups 
are registered in the International Society of Blood Transfusion. Some of them as 
ABO blood groups, MNS, Rh, Lutheran, Kell, Lewis, and Duffy are well studied and 
found their place in clinical practice, but others as Ok, Scianna, Colton, and Knops 
are on their way to be fully understood. The genes of the blood groups are mainly 
autosomal with the exception of XG, XK, and MIC2 genes as they are presented on 
X and Y chromosomes.
The biochemical structure of blood group antigens differs a lot; they can either 
be proteins (Rh, Kell) or glycoproteins and glycolipids (ABO) [1].
ABO blood group system consists of three alleles, dominant A and B, and reces-
sive O, and it is controlled by a gene located on chromosome 9 (9q34.2).
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These genes (A and B) code different glycosyltransferases: glycosyltransferase A 
which adds N-acetylgalactosamine and glycosyltransferase B which adds d-galac-
tose to H-substance. O allele is inactive and does not encode an enzyme, so that H 
substance remains unmodified with a fucose moiety. Combinations of these three 
alleles give us four different blood groups O (I), A (II), B (III), and AB (IV) [2].
It is notable that ABO antigens are expressed not only on the surface of erythro-
cyte, but they can also be found in a variety of tissues and cells, such as the endothe-
lium of blood vessels, neurons, epithelium, platelets, etc.
In recent years, the amount of research on protein-small molecule (metabolite) 
interactions has increased significantly. However, the study of these interactions, 
according to the 2011 Wiley Online Library, is lagging far behind other types of 
interactions, such as protein-protein, protein-DNA, and protein-RNA, in terms of 
publications. Only in 2009 the first publications about protein-metabolite interac-
tions appeared.
From a biochemical point of view, most biological systems work by fulfilling 
their diverse functions by proteins. Due to the revolutionary progress in the study of 
genomics and proteomics, a more accurate idea of the amount of proteins synthe-
sized in the body has now been formed, but there is a weak idea of which proteins 
nonspecifically interact with metabolites [3].
It has been established that intermolecular interactions play a crucial role 
in almost all major biological processes, such as cell regulation, biosynthesis 
and biodegradation, signal transmission, transcription and translation pro-
cesses, the formation of oligomers and multimolecular complexes, packaging 
of viruses, and the immune response, are protein-ligand interactions [4]. The 
polyfunctionality of proteins is due to their ability to change the conformation 
of a molecule when interacting with ligands. Proteins can interact with almost 
all types of molecules: from small compounds—water, metal ions, carbohy-
drates, fatty acids, and cell membrane phospholipids—to high molecular weight 
proteins and nucleic acids. Disruption of protein interactions underlies some 
diseases [5].
This fact provides a key argument that biological and clinical significance of 
blood groups in general and ABO especially extends far beyond our expectations 
and needs to be clarified.
2. Computer modeling of antigen determinants A and B
2.1 Antigen A and its predicted biological activity
It is almost impossible to evaluate the specific properties of the terminal frag-
ments of antigenic structures in an experiment, but with the method of computer 
simulation, one can predict the biological effects of substances.
Glycosylation of protein molecules significantly affects their ability to contact 
with other molecules, which is important for understanding the mechanisms of 
intermolecular interactions, signaling, and adhesion at the cellular and molecular 
levels. The group-specific antigens of the blood ABO system are formed by the gly-
cosylation of transmembrane proteins presented on the surface of red blood cells.
A-Antigen terminal monosaccharide N-acetylgalactosamine contains in the posi-
tion C2 NHCOCH3 group, and B-antigen terminal monosaccharide d-galactose, 
in position C2, contains OH group. Functional groups confer variability in the 
structure of antigens and provide specificity for binding ligands. The presence in 
the structure of the N-acetylgalactosamine acetyl group leads to the disappearance 
of the positive charge.
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N-Acetylgalactosamine is an amino sugar found in almost all glycoproteins. The 
immediate precursor of N-acetylgalactosamine is fructose-6-phosphate. Amino 
sugar is further acetylated with acetyl-CoA.
Monosaccharides can take part in all reactions which are typical for hydroxyl-
containing compounds: they form esters and ethers, acetals and ketals, undergo sub-
stitution and elimination reactions. An important property of monosaccharides is 
their ability to form glycosides due to hydroxyl at the first carbon atom. Elucidation 
of the potential biological activity of antigens, determined by the structural charac-
teristic of the antigenic determinants of the ABO system, is an important task.
We used a program for computer modeling called PASS. Prediction of Activity 
Spectra for Substances (PASS) is a program designed for computer modeling 
created by a group of Russian scientists. This tool is based on the dependence 
between chemical formula of a random substance and its functional activity. 
Chemical formula is described using Multilevel Neighborhoods of Atom (MNA) 
descriptors, the combination of which is unique for each substance. The user 
gets the list of probable activities based on the program’s self-educating “training 
set,” which aggregates data on active compounds from databases, publications, 
and patents, marked with Pa (probability to be active) and Pi (probability to be 
inactive), placed in the order from the maximum Pa to the minimum one. The 
program uses the Bayesian approach with some modifications for calculating the 
Pa and Pi (for more detailed information, see [6, 7]). In our study we chose effects 
with Pa >0.5. Total number of biological activities in the database is 4130, 501 of 
them are pharmacological effects, 3295 are molecular mechanisms of action, 57 
are toxic effects, 199 are mediated metabolic actions, and 29 are influences on 
gene expression.
We have identified a significant number of previously unknown properties and 
mechanisms of action for the antigenic determinant antigen A, namely, 99 out of 
501 possible pharmacological effects, 304 out of 3295 possible molecular mecha-
nisms of action, 17 out of 57 adverse and toxic effects, 12 of 199 metabolic-related 
activities, 2 of 29 effects regulating the expression of genes, and 5 of 49 effects 
associated with the transport of substances. We chose biological activities with a 
probability of Pa greater than 0.5. The PASS program allowed us to establish that 
the antigenic determinant of antigen A exhibits the following pharmacological 
effects (Table 1).
It is predicted that the antigenic determinant of antigen A exhibits antibacterial, 
immunostimulating, antifungal, antiviral, and pharmacological effects, as well as 
antibiotic properties.
Pharmacological effect Pa Pi Pa − Pi
Membrane permeability agonist 0.840 0.006 0.834
Antibacterial 0.707 0.005 0.702
Immunostimulating 0.697 0.07 0.690
Antineoplastic 0.654 0.016 0.638
Antifungal 0.632 0.013 0.619
Antiviral 0.620 0.011 0.609
Angiogenesis stimulator 0.577 0.012 0.565
Vasoprotector 0.552 0.045 0.507
Table 1. 
Predicted pharmacological effects of antigen A.
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ABO phenotypic analysis of blood groups is often used to detect the degree of 
susceptibility of a person to infectious diseases. In the literature, there are data in 
which it is noted that the interaction of certain parasites and bacteria with human 
cells depends on the presence of certain blood groups [8].
Thus, antigen A exhibits high adhesive activity against lactic acid bacteria. Some 
of the antigens affect the humoral and cellular response [9].
For the oligosaccharide of the antigen A, the antineoplastic effect on the cancer of 
various etiologies and localization is predicted: gastric and lung cancer, sarcoma, leuke-
mia, and cancer of the brain and ovaries. Numerous studies have shown an association 
between ABO blood groups and the risk of developing various types of cancer [10].
With a high degree of probability, the antigen A is able to regulate angiogen-
esis and has a potential vasoprotective effect, as well as an effect of inhibitor of 
membrane permeability and integrity. The formation of new blood vessels in the 
organ or tissue is activated only when the damaged tissues are regenerated. Some 
factors, depending on the dose, can be both inducers of angiogenesis and inhibitors 
[11]. Many predicted effects of the antigenic determinant of antigen A are realized 
through the molecular mechanisms of its action (Table 2).
It is predicted that the oligosaccharide of the antigen A can act as an agonist of 
nerve growth factor, tumor necrosis factor, hyaluronic acid, α-interferon, interleu-
kin-2, and tissue kallikrein inhibitor. The stimulating effect of the oligosaccharide 
antigen A on the activity of caspases 3, 8, and 9, participants in the apoptosis 
process, is predicted. As it is known, all caspases are synthesized in an inactive form 
and are activated when necessary by initiating caspases in the process of partial 
proteolysis. Probably, the antigenic determinant A, by activating caspases, can 
trigger a signal chain of programmed cell death.
Analyzing molecular mechanisms of action of antigenic determinants A, 
we paid attention to the inhibitory effect, to a number of carbohydrate metabo-
lism enzymes, complex lipid metabolism, and protein biosynthesis process. 
Molecular mechanism of action Pa Pi Pa − Pi
Inhibitor of CDP-glycerol phosphotransferase 0.837 0.006 0.931
Α-glucosidase inhibitor 0.826 0.001 0.825
Analogue of insulin 0.755 0.003 0.552
Antagonist of membrane integrity 0.731 0.009 0.713
Lactase inhibitor 0.718 0.007 0.711
Nerve growth factor agonist 0.715 0.007 0.708
Inhibitor ceramide glycosyltransferase 0.713 0.010 0.703
Aspartyl transferase inhibitor 0.708 0.007 0.701
Hyaluronic acid agonist 0.701 0.002 0.699
B-glucuronidase inhibitor 0.661 0.005 0.656
Caspase stimulator 0.646 0.005 0.641
N-acetylglucosamine transferase inhibitor 0.636 0.003 0.633
Glycerol monooxidase inhibitor 0.628 0.025 0.603
A-interferon agonist 0.595 0.019 0.576
TNF agonist 0.550 0.019 0.531
IL-2 agonist 0.517 0.011 0.503
Table 2. 
Predicted molecular mechanisms of action of antigen A.
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Oligosaccharide antigen A may inhibit the activity of enzymes involved in the 
metabolism of simple carbohydrates, such as α-glucosidase, β-glucuronidase, and 
β-galactosidase, and in the exchange of complex carbohydrates, predominantly 
heteropolysaccharides—α-N-acetyl-glucosaminidase, dolichol glycosyltransferase, 
and GDP-mannose-6-dehydrogenase, which creates the possibility of inhibiting the 
metabolism of the components of the extracellular matrix of connective tissue—
glycoproteins and proteoglycans. Dolichol glycosyltransferase plays a leading role in 
the glycosylation of membrane proteins.
It is predicted that the oligosaccharide of the antigen A can be an agonist of hyal-
uronic acid. Hyaluronic acid belongs to the innate immunity system and is involved 
in tissue regeneration, as evidenced by the likely manifestation of the pharmaco-
logical effects of tetrasaccharide A, as immunostimulating and vasoprotective.
Also, we predicted possible toxic effects (Table 3).
The effect of carbohydrate determinants of antigen A on the metabolism of 
complex lipids is predicted, and the molecular mechanism of action is inhibi-
tion of the activity of CDP-glycerol glycerophosphotransferase, ceramide 
glycosyltransferases, ganglioside galactosyltransferases, and galactosylglucosyl-
ceramidase, involved in the synthesis of phospho- and glycolipids, necessary for 
the construction of cell membrane structures. Glycolipids play an important role 
in making cell-to-cell contacts; some serve as a kind of receptor for a number of 
bacterial toxins.
The possibility of an inhibitory effect on a gene expressing telomerase was 
predicted. About 85% of cancer cells acquire unlimited replicative potential due to 
the reactivation of a specific telomerase enzyme [12].
After analyzing the data obtained by computer prediction, we can conclude that 
the immunochemical specificity of the antigenic determinant of antigen A is real-
ized by the characteristic and diverse biological activity and toxicity.
2.2 Antigen B and its biological activity
The antigenic determinant of antigen B contains terminal d-galactose, at posi-
tion C2 where it has a hydroxyl group.
d-Galactose itself can enter into the reactions of alkylation, acylation, reduc-
tion, and oxidation. Analysis of the data of the probable biological activities of 
the antigenic determinant of antigen B showed 106 out of 501 possible pharma-
cological effects, 311 of the 3295 probable molecular mechanisms of action, 16 
of 57 adverse and toxic effects, 15 of 199 metabolically mediated actions, 3 of 29 
effects regulating gene expression, and 6 of 49 effects associated with transport of 
substances. We chose biological activities with a probability of Pa greater than 0.5. 
The pharmacological effects of the antigenic determinant of antigen B are shown 
in Table 4.
Toxic effects Pa Pi Pa − Pi
Hypokalemia 0.744 0.033 0.711
Nephrotoxicity 0.734 0.018 0.716
General toxicity 0.691 0.038 0.653
Bronchoconstrictor 0.647 0.035 0.612
Cardiotoxicity 0.644 0.031 0.613
Hepatotoxicity 0.611 0.051 0.560
Embryotoxic 0.504 0.012 0.492
Table 3. 
Possible toxic effects of antigen A.
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Molecular mechanism of action Pa Pi Pa − Pi
Inhibitor of CDP-glycerol phosphotransferase 0.806 0.008 0.798
Α-glucosidase inhibitor 0.799 0.001 0.798
Antagonist of membrane integrity 0.764 0.010 0.754
Agonist of hyaluronic acid 0.720 0.001 0.719
Nerve growth factor agonist 0.701 0.009 0.709
Insulin agonist 0.699 0.004 0.695
Antagonist of interferon 0.603 0.017 0.586
Inhibitor of glycerol oxidase 0.638 0.023 0.615
Caspase 8 activator 0.625 0.007 0.618
TNF regulator 0.570 0.014 0.556
B-galactosidase inhibitor 0.558 0.003 0.555
IL-2 agonist 0.526 0.018 0.508
Caspase 3 activator 0.514 0.014 0.500
Glycosyltransferase inhibitor 0.512 0.004 0.508
Inhibitor of protein synthesis 0.509 0.007 0.502
Table 5. 
Predicted molecular mechanisms of action of antigen B.
Many effects and mechanisms of action are common for both antigen A and 
antigen B, but they are characterized by different degrees of probability of mani-
festation (Pa value). It is predicted that the antigen B is able to exhibit antibacterial, 
antiviral, antifungal, and pharmacological effects. According to the literature, 
group-specific antigens A and B can play a direct role in the susceptibility of the 
infection, acting as receptors or co-receptors for microorganisms, parasites, and 
viruses (Table 5).
In the study, Kato shows that carbohydrates can act not only as receptors for 
various microbes but also function as a barrier to infection [13].
Numerous molecular mechanisms of the action of antigen B tetrasaccharide 
have been predicted, in particular the inhibitory effect on the activity of a num-
ber of enzymes involved in the metabolism and stimulating effects on various 
bioregulators.
Pharmacological mechanism Pa Pi Pa − Pi
Agonist of membrane permeability 0.863 0.005 0.858
Antibacterial 0.688 0.05 0.683
Immunostimulatory 0.668 0.008 0.660
Antineoplastic 0.630 0.021 0.609
Antifungal 0.622 0.014 0.608
Vasoprotector 0.599 0.042 0.557
Angiogenesis activator 0.591 0.010 0.581
Antiviral 0.583 0.014 0.569
Antibiotic 0.524 0.005 0.519
Table 4. 
Predicted pharmacological effects of antigen B.
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The stimulating effect of oligosaccharide B on the activity of caspases 3 and 
8 is predicted; it can act as an agonist of hyaluronic acid, nerve growth factor, 
interleukin-2, and interferon antagonist. It has been established that galactooligo-
saccharides selectively increase the content of useful intestinal microbes, as well as 
C-reactive protein and interleukins [14].
The probable effect of oligosaccharide B on the expression of the telomerase 
gene (Pa 0.785) and the transport of electrons in mitochondria (Ra 0.504) is shown. 
Oligosaccharide B is highly likely to be a substrate for cytochrome P-450 2J2 (Pa 
0.980), glutathione-S-transferase (0.907), and cyclooxygenase (Pa 0.759).
Using PASS we also identified possible toxic effects (Table 6).
The PASS program revealed that the antigenic determinant of antigen B can 
exhibit a variety of biological effects and molecular mechanisms of action that 
regulate various physiological and metabolic processes in the body.
The role of carbohydrates as key biological ligands is well known. This is due to 
the high degree of isomerism, possible within individual carbohydrate units, in a 
variety of ways to combine monosaccharides, among themselves, different varia-
tions of substituents (acetyl, sulfate) and flexibility of carbohydrate chains.
With the development of computational methods for studying protein-ligand 
interactions, it became possible to determine the type of bonds and the most important 
positions of atoms “C” in monosaccharides for the formation of an antigen-antibody 
complex. Using the molecular docking method, Stanca-Kaposta with a group of scien-
tists found that hydrogen bonds and hydrophobic and van der Waals interactions are 
involved in the formation of an antigen-antibody association [15]. Monosaccharides 
of antigens can act as acceptors of hydrogen, and amino acid residues of paratope 
antibodies can serve as hydrogen donors. Most commonly, hydrogen bonds form atoms 
“C” at positions 3 and 5 in terminal galactose (antigen B) and atoms “C” at position 5 in 
N-acetylgalactosamine (antigen A). Accessibility of the nitrogen atom in the GalNAc 
epitope to participate in the formation hydrogen bonds are hampered by the presence 
of an acetyl group. The “C” atoms in position 6 are involved in hydrophobic and van 
der Waals interactions, both in galactose and in N-acetylgalactosamine [16].
In studies by J. Milland, it was found that in the N-acetylated version of the epit-
ope of antigen A, the interaction of the acetyl group of the epitope with the tyrosine 
35 of the immunoglobulin heavy chain precludes further penetration of the antigen 
into the antibody’s binding site. In contrast, the Gal epitope of antigen B penetrates 
deeper into the antibody’s binding site, and the second galactose antigenic determi-
nant participates in hydrophobic interactions with tryptophan at position 36 of the 
immunoglobulin heavy chain [17]. ABO antigens, like other glycoconjugates, are 
important intercellular adhesion mediators and participants in signal transduction. 
Due to the diversity of biological effects manifested, oligosaccharides A and B are 
evaluated from a new perspective side as biologically active compounds and not 
only blood group antigens that protect blood cells [18].
Toxic effects Pa Pi Pa − Pi
Hypokalemia 0.763 0.030 0.733
Nephrotoxicity 0.709 0.022 0.687
Bronchoconstrictor 0.703 0.026 0.677
Cardiotoxicity 0.687 0.023 0.664
General toxicity 0.667 0.043 0.624
Hepatotoxicity 0.590 0.057 0.533
Table 6. 
Possible toxic effects of antigen B.
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Computer modeling exists as a way of combining the microscopic world of 
molecules and experimental results, which helps to confirm our understanding 
of metabolic processes and propose new directions for research. For many of the 
predicted types of activity of compounds in the available literature, experimental 
evidence has not been found, since these organic compounds are difficult for 
conformational analysis. Computational methodology makes it possible to obtain 
structures of compounds at the atomic level and information about activity with 
an accuracy equivalent to or greater than can be obtained in an experiment. The 
prognostic and interpretative program PASS has helped to better present the 
mechanisms of action of the studied metabolites and carbohydrate determinants of 
antigens A and B in relation to the main body systems.
3. ABO system as a marker of metabolic state
We selected 3678 healthy people with no chronic somatic and dental diseases, as 
well as latent socially significant viral infections (hepatitis B and C, HIV). Then, we 
performed a complex biochemical testing of blood with 40 parameters, complete 
blood count with 21 parameters, and hemostasiograms with 8 parameters. Studies 
of concentration of total protein; albumin; immunoglobulins A, G, and M; urea; 
creatinine; uric acid; total and direct bilirubin; C-reactive protein; alanine amino-
transferase; aspartate aminotransferase; gamma-glutamyltranspeptidase; creatine 
kinase and creatine kinase-MB fraction; total cholesterol content; triglycerides; 
high-density lipoprotein and low-density lipoprotein; lipase activity; the coefficient 
of atherogenicity; glucose concentration; lactate dehydrogenase; alpha-amylase; 
alkaline phosphatase activity; and magnesium, calcium, phosphorus, and iron levels 
were carried out on an automatic biochemical analyzer “Hitachi-902” and “Integra 
800” (“Roche,” Japan) with the help of a commercial reagent kit from the company 
“Roche” (Germany). Intra-laboratory quality control when performing studies was 
carried out using control serum Precinorm and Precipath (Roche, Germany).
Complete blood count was performed using an automated hematology analyzer 
Sysmex KX-21 (Roche, Japan) using a commercial set of reagents produced by 
Roche (Germany). We measured distribution curves for the size of erythrocytes, 
leukocytes, and platelets, as well as analytical results for 18 parameters: the number 
of erythrocytes, leukocytes, and platelets; the content of hemoglobin and hema-
tocrit; the average volume of erythrocytes and platelets; the average content and 
average concentration of hemoglobin in the erythrocyte; the width of the distribu-
tion of erythrocytes and platelets by volume; the relative and absolute content of 
neutrophils, medium cells, and lymphocytes; and the ratio of large platelets. The 
morphological study of blood cells was performed using a Zeiss light microscope 
using a unified method. The erythrocyte sedimentation rate was determined using 
a Panchenkov unified micromethod. The functionality of platelets was assessed by 
the method of visual detection of the start time of aggregation with different induc-
tors (ADP, with a universal aggregation inducer (UIF), collagen).
Statistical processing of the results was carried out using the statistical pack-
age SPSS 12.0 and Microsoft Excel 2007. The statistical characteristics were used: 
arithmetic average (M), standard arithmetic average error (m), median (Me), max, 
min, and 95% interval. Indicators of skewness and steepness reflect the asymmetry 
of distribution; normality tests were evaluated using the Kolmogorov-Smirnov 
test with the Lilyfors and Shapiro-Wilkie corrections. We used the nonparametric 
Mann-Whitney U test with the amendment of Bonferroni as an alternative to the 
Student’s t-test. Taking into account the deviation from normality of various values 
of dispersions, a nonparametric analogue of dispersive analysis was used—the 
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Kruskal-Wallis analysis. To study the correlation of blood parameters, Spearman’s 
correlation analysis was used.
The data we obtained supplemented information about the connection of 
certain diseases with blood groups (Table 7).
On the basis of the study of the metabolism in the O (I)—AB (IV) blood groups, 
we determined the trends characterizing their biological variability and identified 
the parameters associated with a specific blood group (Table 8).
According to the specifics of these indicators, we attributed the owners of 
AV (IV) blood groups to the protein type, since they have the highest protein 
availability and they are less likely to get ill. It is known that A (II) carriers of the 
second blood group suffer from a wide range of diseases, including infectious 
diseases. They have an immunological memory of old and fresh contacts with 
bacterial and viral agents. The level of lipids can be conditionally attributed to 
the lipid type. In the presence of the first blood group, a high level of specific and 
nonspecific protection factors is characteristic. For them, a preferential connec-
tion with somatic pathology has been identified. Owners of the third blood group 
are characterized by sufficient good health. They have the highest level of albu-
min, cholesterol [19].
The identified features of the metabolic profile in individuals with different 
blood groups are the rationale for the individualization of standards for each 
person. In the future, every citizen should have his own health passport.
In accordance with the results obtained, in persons with O (I) blood group, a 
lower number of erythrocytes are noted with a relatively small volume of cells. 
Blood group Possibility of pathological process development Authors
O (I) Peptic ulcer disease
Stomach cancer
Hip joint dysplasia
Myasthenia
Mutation (F7)
Women papillomavirus infection
Acute inflammatory processes in women 
reproductive system
Sympathetic ophthalmia
Laryngeal cancer
HCV
Risk factor for ovarian reserve
Hemophilic patients with anemia
Rare bleeding disorders
Rare intraductal papillary mucinous neoplasm
Rare case of malaria
Rare hepatocellular carcinoma
Rare postpartum blood loss
U. Altuhov (1983); G. Drannik, 
G. Dizik (1990)
A. Tananyan (2001); 
S. Garmonov et al. (2006)
Wang Qing-yun (2007); 
Bogdanov N.N. (2015)
B. Bjorkholmet al (2001)
M. Aspholm-Hurtig et al. (2006)
I. Taboridze (1991)
B. Gehte (1996)
T. Subbotina (2012)
E. Shevchenko (2010)
L. Arkhipova (2012)
T. Jin et al. (2016)
X. Li et al.(2016)
J. Deng (2016)
U. Kosyakova
F. Gilmiarova
L. Spieza (2018)
K. Poruk (2018)
A. Degarege (2018)
F. Liu (2018)
M. Kahr (2018)
Chronic prostatitis with benign prostatic 
hyperplasia
Bladder cancer
Urolithiasis
The increased spontaneous platelet aggregation
CHD
Shatohin M., Konoplya A., 
Dolgareva C. A., (2011)
Mayskov I., (2013)
Gusein-zade, R., (2013)
Gergesova E., (2011)
Biswas S., Ghoshal P.K., Halder 
B., Mandal N. (2013)
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Blood group Possibility of pathological process development Authors
A (II) Coronary artery disease
Rheumatic diseases
CHD
Bronchial asthma
Allergies
Cholecystitis, cholelithiasis
Diabetes mellitus
Meningococcal infection
Secondary purulent meningitis
Leiden mutation (F5)
Prothrombin mutation (F2)
Platelet receptors mutation (GpIa, GpIIIa)
Thromboembolism
HIV
The combined prevalence of HIV and hepatitis C
Hepatitis B
Preeclampsia and fetal hypotrophy
Iron deficiency anemia
Onychomycosis
Chronic generalized periodontitis
Helicobacter pylori antibodies in oral fluid
Chronic prostatitis
The combination of chronic prostatitis with benign 
prostatic hyperplasia
Breast cancer
Tuberculosis
Atherosclerosis with complications
Appendicular peritonitis in children
Hemolytic disease of the newborn with A-blood 
group mothers
Pancreatic cancer
Gastroesophageal reflux disease
Asthma
Bladder cancer
Mediterranean fever
Z. Chen et al. (2016)
E. Suslova (2012)
E. Meshalkin (1981)
M. Freidin et al. (2006)
M. Rafalovich et al. (1982)
E. Chichenko, U. Koshel (1975)
B. Geht et al.(1995)
G. Dizik et al.(1986)
A. Veselov, N. Malushkina 
(1988)
U. Rudometov et al. (1981)
I. Danilov (2010)
R. Vitkovskiy
E. Gergesova (2011)
G. Liumbruno (2013)
S. Vasan (2016)
F. Gilmiyarova, V.Radomskaya 
et al. (2007)
Shatohin M., Konoplya A. (2011)
Shatohin M., Konoplya A. (2011)
Yanchenko M. (2011)
Bektasova M., Kapcov V. (2014)
Suslova E., Vasilyeva L. (2012)
Gavrilyuk V. (2011)
Doyle B., Quigley J. et al. (2014)
Rizzato C., Campa D. et al. 
(2013)
Sadreddini M., Rasmi Y. et al. 
(2011)
B. Mroczek et al. (2018)
D. Stakisaitis (2018)
A. Erden
B (III) Pneumonia
Postoperative infection
Osteochondrosis with radicular syndrome
Sciatica
MGTFR mutation
Chronic inflammatory processes in women 
reproductive system
Damage of the coronary artery associated with 
Kawasaki disease
Chronic prostatitis
The combination of chronic obstructive bronchitis 
with coronary heart disease
Thrombosis
Brain neoplasms
Gingivitis
Periodontal disease
HBV
Averbah M. (1985)
Dizik G. (1990)
Subbotina T.(2012)
Shevchenko E. (2010)
K. Jamamuru (2012)
Shatohin M., Konoplya A. (2011)
Suslova E., Vasilyeva L. (2013)
Subbotina T., Petuhova A. 
(2012)
Stolbova E., Bane B. (2009)
Mortazavi H., Lotfi G. (2015)
Ramamoorthy B., Varghese S.S. 
(2015)
T. T. Lao et al. (2014)
AB (IV) Acute respiratory viral infection
Sore throat
Chronic tonsillitis
Sinusitis
Nasopharynx cancer
L. Grebenshikov (2001),
S. Garmonov et al. (2006)
Sheng Liming (2013)
Table 7. 
Possibility of pathological process development in ABO blood groups.
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The level of hemoglobin in the blood is the lowest, while the saturation of each 
erythrocyte with hemoglobin is maximum, which ensures full blood transport of 
gases. A (II) of the second blood group is characterized by the lowest hematocrit 
value, the average hemoglobin content in one erythrocyte, the average platelet 
volume, and the maximum indicator of the number of leukocytes, neutrophils, and 
lymphocytes. Carriers of B (III) blood group showed the largest volume of platelets 
and the maximum of the average concentration of hemoglobin in one erythrocyte. 
In persons with AB (IV) blood group, the highest absolute and relative content 
of lymphocytes, which are the basis of cellular and humoral immunity, is noted. 
Tendency to lymphocytosis, a higher level of the spectrum of immunoglobulins 
is an indicator of the intensity of specific resistance and sufficient compensatory 
reserve in patients with AB (IV) blood group (Figure 1).
ABO blood group
Characteristic O (I) A (II) B (III) AB (IV)
Protein N N − +++
Albumin − −−− +++ ++
α1 +++ N −− N
α2 +++ N −− −
β-Globulin +++ N −− −
γ-Globulin +++ −−− −− −
IgA +++ −−−− −−− N
IgG N +++ −−− N
IgM N +++ −−− N
Thymol turbidity test N +++ − −−−−
CRP +++ N −−−− −−
Urea +++ N N −−−−
Uric acid −−−− + N ++
Creatinine N N N N
Bilirubin + − + −−−−
ALT N N ++ ++
AST −−−− − ++++ N
GGT ++++ −−− N −−
Cholesterol + −−− +++ −−
TAG +++ ++++ − −−−−
HDL −− −− N N
LDL −− − −− ++
Lipase − − ++ −−−−
Glucose −−− −− ++ −−
Lactate dehydrogenase +++ N +++ −−−−
Amylase +++ N −−− ++
Table 8. 
Metabolic characteristic of ABO blood groups (N stands for average results for general population; “+” and 
“−”—the degree of deviation compared to general population).
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4. Conclusions
The results obtained in silico by computer prediction with PASS program show 
that antigens A and B influence on intermolecular processes, protein-protein 
interaction, maintain balance by regulating protein, carbohydrate, lipid metabo-
lism, antioxidant processes, and tissue respiration quite differently which can be 
explained with their structure and conformational features.
The series of experiments clearly showed biodiversity in metabolic state of dif-
ferent ABO groups which allow us to create metabolic passport for each blood group 
summarizing the key data [19].
We found out that the carriers of O (I) blood group suffer from somatic diseases 
more recently than the other blood group carriers, while the carriers of A blood 
group are predisposed for infectious diseases, and the carriers B (III) and AB (IV) 
blood groups are more likely to show metabolic stability.
To summarize, methods of molecular modeling and forecasting allow us to 
broaden the fundamental knowledge about the molecules’ properties and to 
Figure 1. 
Biological diversity associated with ABO blood groups.
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successfully predict new possible biological effects, as well as molecular mecha-
nisms for its realization in complex interactions of ligands and their targets.
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